Isodiol International Inc. (
CSE:ISOL,
OTCQB: ISOLF,
Forum) announced Wednesday that it has entered a Binding Agreement to acquire 25% of pharmaceutical manufacturer
Canadian National Pharma Group Inc.
CN Pharma is in the final stages of receiving its Licensed Dealer status with Health Canada to produce cannabis and hemp extracts at it’s 9,750 sq. ft. space in Abbotsford, B.C. Under the agreement, Isodiol has complete exclusivity to the facility and can expand its ownership to an overall controlling interest.
Marcos Agramont, CEO of Isodiol, said in a press release that their intent is to become a global provider of products from personal care, to beverages and edibles, topicals, nutraceutical supplements, and capsules.
More information can be found
here.
Isodiol made the news recently when the company acquired a 100% stake in hemp product seller Be Tru Organics.
FULL DISCLOSURE: Isodiol International Inc. is a paid client of Stockhouse Publishing.